<DOC>
	<DOCNO>NCT03040687</DOCNO>
	<brief_summary>Enterotoxigenic Escherichia coli ( ETEC ) major cause diarrhea worldwide . Vaccines therapeutic development prevent ETEC disease child traveler . One approach use passive protection ( antibody ) prevent infection . The purpose study assess safety serum-derived bovine immunoglobulins healthy adult subject orally administer estimate protective efficacy preparation moderate-severe diarrhea upon challenge ETEC strain B7A .</brief_summary>
	<brief_title>Efficacy B7A BSIgG Against E. Coli Strain B7A Challenge</brief_title>
	<detailed_description>Enterotoxigenic Escherichia coli ( ETEC ) one common cause infectious diarrhea child resource limited country , also frequent cause traveler 's diarrhea civilian military traveler endemic country . ETEC strain express variety colonization factor ( CF ) help attach intestinal wall . Each colonization factor one surface antigens ( CS ) . One major surface antigens ETEC CS6 . Vaccines treatment prevent ETEC disease development . Some target specific enterotoxins colonization factor . For 40 year , use ETEC human challenge study understand ETEC disease process , immune response , recently , determine whether treatment vaccine protective effective mitigating disease . B7A CS6 express ETEC challenge strain currently use . A modality show success prevention diarrhea passive , oral administration bovine milk IgG specific activity viral , bacterial parasitic enteropathogens . Passive oral administration Bovine Serum Immunoglobulins ( BSIgG ) may protect ETEC-mediated infectious diarrhea . The hypothesized mechanism protection stem passive administration bovine anti-tip adhesion fimbria antibody prevent adherence human small intestine ( initial step pathogenesis ) , thereby prevent downstream pathogenic process symptomatic illness . This study establish foundation evaluate BSIgG product numerous ETEC CFs . This study explore anti-B7A anti- CS6 BSIgG provide protection oral challenge B7A healthy adult volunteer . There two inpatient admission approximately 30 subject ( 60 total ) . They receive one three investigational product ( IP ) three time daily follow meal begin 2 day prior challenge . Each volunteer challenge CS6 express ETEC B7A Day 0 . The investigational product/placebo administer total 7 day , antibiotic treatment administer . The investigator hypothesize anti-CS6 BSIgG provide protection B7A mediate moderate severe diarrhea upon challenge .</detailed_description>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Male female 18 50 year age , inclusive . General good health , without significant medical illness , abnormal physical examination finding clinical laboratory abnormality determine principal investigator ( PI ) PI consultation research monitor sponsor . Demonstrate comprehension protocol procedure knowledge ETEC illness pass write examination ( pas grade â‰¥ 70 % ) Willing participate inform consent obtain . Available planned followup visit . Negative serum pregnancy test screen negative serum and/or urine pregnancy test day admittance inpatient phase female subject childbearing potential . Females childbearing potential must agree use efficacious hormonal barrier method birth control study . Abstinence acceptable . Female subject unable bear child must document ( e.g. , tubal ligation hysterectomy ) . General health criterion Presence significant medical condition , ( e.g . psychiatric condition gastrointestinal disease , peptic ulcer , symptom evidence active gastritis gastroesophageal reflux disease , inflammatory bowel disease , alcohol illicit drug abuse/dependency , laboratory abnormality opinion investigator precludes participation study . Immunosuppressive illness Immunoglobulin A ( IgA ) deficiency ( serum IgA &lt; 7 mg/dL limit detection assay ) Evidence confirm infection HIV , HBsAg , Hepatitis C Virus ( HCV ) , confirmatory assay . Use investigational product within 30 day precede receipt investigational product , plan use active study period Significant abnormalities screen lab hematology serum chemistry , determine PI PI consultation research monitor sponsor . Lactation breastfeed . Researchrelated exclusion applicable challenge History microbiologically confirm ETEC cholera infection last 3 year . Occupation involve handle ETEC Vibrio cholerae currently , past 3 year . Travel country ETEC cholera infection endemic ( develop world ) within 3 year prior dose . Symptoms consistent Travelers ' Diarrhea concurrent travel country ETEC infection endemic ( develop world ) within 3 year prior dose , OR plan travel endemic country length study . Vaccination ingestion ETEC , cholera , E coli heat labile toxin within 3 year prior dose . Any prior experimental infection ETEC strain B7A . Studyspecific Exclusion Criteria ( potential increase risk complicate outcome ascertainment ) Abnormal stool pattern ( few 3 per week 3 per day ) . History diarrhea 2 week prior plan inpatient phase . Regular use laxative , antacid , agent low stomach acidity ( regular define least weekly ) . Use antibiotic 7 day receipt investigational</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ETEC</keyword>
	<keyword>Escherichia coli</keyword>
	<keyword>enteritis</keyword>
	<keyword>challenge</keyword>
	<keyword>CS6</keyword>
	<keyword>B7A</keyword>
</DOC>